Why so many zvz

Clinical drug monitoring. Infectious diseases. Explore the Test Directory. Explore the Test Directory Our Test Directory includes detailed information, guides, and references for many of our tests. As your patients get back to routine care, ensure your labs are ready. Be ready for new healthcare needs created by COVID As your patients get back to routine care, ensure your labs are ready.

Lab management. Lab operations Lab testing consolidation Lab stewardship Clinical solutions Getting back to care Outreach services. Lab operations. Lab testing consolidation. Lab stewardship. Clinical solutions. Getting back to care. Outreach services. Meet our clinical experts. Complement your expertise with ours to improve test selection and interpretation.

Meet our clinical experts Complement your expertise with ours to improve test selection and interpretation. Explore lab stewardship. Explore lab stewardship Drive efficiency and better patient outcomes.

Pharma solutions. Lab optimization Strategic opportunities Clinical support Diagnostic excellence Academic collaboration Population health Enterprise content management. Lab optimization. Strategic opportunities. Clinical support. Diagnostic excellence. Academic collaboration.

Population health. Enterprise content management. Technology solutions to elevate operational efficiency. Capture, store, access, share, and manage content across your enterprise. Technology solutions to elevate operational efficiency Capture, store, access, share, and manage content across your enterprise.

Solutions for lab managers. Solutions for lab managers The tools and services to make your lab more efficient and optimize patient care. Drug screening International drug testing Lab spend management Employer population health.

Drug screening. International drug testing. Lab spend management. Employer population health. Shingles is an extremely painful condition typically occurring in older nonimmune adults or those with waning immunity to VZV and in patients with impaired cellular immunity. Individuals at risk for severe complications following primary VZV infection include pregnant women, in whom the virus may spread through the placenta to the fetus causing congenital disease in the infant.

Additionally, immunosuppressed patients are at risk for developing severe VZV-related complications, which include cutaneous disseminated disease and visceral organ involvement. The presence of IgM-class antibodies to VZV is suggestive of acute or recent infection however results should be correlated with clinical presentation.

This result should not be used alone to diagnose VZV infection and should be interpreted in the context of clinical presentation. These individuals are considered to have protective immunity to reinfection. However, a negative result does not rule-out VZV infection. The specimen may have been drawn before the appearance of detectable antibodies. Negative results in suspected early VZV infections should be followed by testing a new serum specimen in 2 to 3 weeks.

Vaccines and preventable diseases: shingrix recommendations. Chickenpox varicella : signs and symptoms. Shingles herpes zoster : signs and symptoms. Collecting specimens for varicella zoster virus VZV testing. Clinical features of varicella-zoster virus infection. TORCH infections. Clin Perinatol. Chickenpox varicella : varicella reporting and surveillance. World Health Organization.

WHO vaccine preventable diseases surveillance standards: varicella. Subscribe for Updates. Editorial Policy. Learn more. Cite this page. Topic Name. Message If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

Leave this field blank. Quick Answers for Clinicians What is the role of laboratory testing for varicella-zoster virus? What are some atypical presentations of varicella-zoster virus infection, and how do they influence testing? Where can I find information on varicella-zoster virus vaccination recommendations? Clinical Presentation of Varicella-Zoster Virus Chickenpox Varicella The Council of State and Territorial Epidemiologists CSTE -approved varicella case definition describes varicella as an illness with acute onset of diffuse generalized maculopapulovesicular rash without other apparent cause.

Shingles Herpes Zoster Herpes zoster generally presents as a painful, itchy, or tingly rash in one or two adjacent dermatomes localized zoster. Indications for Testing Classic Varicella-Zoster Virus Presentation Laboratory testing is generally not necessary or recommended for persons who exhibit canonical presentation of VZV infections.

During reactivation, the virus migrates along neural pathways to the skin, producing a unilateral rash, usually limited to a single dermatome. Shingles is an extremely painful condition typically occurring in older nonimmune adults or those with waning immunity to VZV and in patients with impaired cellular immunity. Individuals at risk for severe complications following primary VZV infection include pregnant women, in whom the virus may spread through the placenta to the fetus, causing congenital disease in the infant.

Additionally, immunosuppressed patients are at risk for developing severe VZV-related complications, which include cutaneous disseminated disease and visceral organ involvement. The reported AI value is for reference only. This is a qualitative test and the numeric value of the AI is not indicative of the amount of antibody present. AI values above the manufacturer recommended cutoff for this assay indicate that specific antibodies were detected, suggesting prior exposure or vaccination.

The presence of detectable IgG-class antibodies indicates prior exposure to the varicella-zoster virus VZV through infection or immunization. Individuals testing positive are considered immune to varicella-zoster.